PT  - JOURNAL ARTICLE
AU  - Choreño-Parra, José Alberto
AU  - Jiménez-Álvarez, Luis Armando
AU  - Cruz-Lagunas, Alfredo
AU  - Rodríguez-Reyna, Tatiana Sofía
AU  - Ramírez-Martínez, Gustavo
AU  - Sandoval-Vega, Montserrat
AU  - Hernández-García, Diana Lizzeth
AU  - Choreño-Parra, Eduardo M.
AU  - Balderas-Martínez, Yalbi I.
AU  - Martinez-Sanchez, Mariana Esther
AU  - Márquez-García, Eduardo
AU  - Shiutto, Edda
AU  - Moreno-Rodríguez, José
AU  - Barreto-Rodríguez, José Omar
AU  - Vázquez-Rojas, Hazel
AU  - Centeno-Sáenz, Gustavo Iván
AU  - Alvarado-Peña, Néstor
AU  - Salinas-Lara, Citlaltepetl
AU  - Sanchez-Garibay, Carlos
AU  - Hernández, Gabriela
AU  - Mendoza-Milla, Criselda
AU  - Domínguez, Andrea
AU  - Granados, Julio
AU  - Mena-Hernández, Lula
AU  - Pérez-Buenfil, Luis Ángel
AU  - Domínguez-Cheritt, Guillermo
AU  - Cabello-Gutiérrez, Carlos
AU  - Luna, Cesar
AU  - Salas-Hernández, Jorge
AU  - Santillán-Doherty, Patricio
AU  - Regalado, Justino
AU  - Hernández-Martínez, Angélica
AU  - Orozco, Lorena
AU  - García-Latorre, Ethel Awilda
AU  - Hernández-Cárdenas, Carmen M.
AU  - Khader, Shabaana A.
AU  - Zlotnik, Albert
AU  - Zúñiga, Joaquín
TI  - Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1)
AID  - 10.1101/2020.08.10.20170761
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.10.20170761
4099  - http://medrxiv.org/content/early/2020/08/14/2020.08.10.20170761.short
4100  - http://medrxiv.org/content/early/2020/08/14/2020.08.10.20170761.full
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to cause severe disease manifestations in the lungs. Although clinical descriptions of COVID-19 are currently available, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological characteristics of patients with COVID-19 and pandemic influenza A(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue injury markers, a histological pattern of alveolar pneumonia, and higher levels of IL-1RA, TNF-α, CCL3, G-CSF, APRIL, sTNF-R1, sTNF-R2, sCD30, and sCD163 in influenza patients. Conversely, dry cough, gastrointestinal symptoms, interstitial lung pathology, increased Th1 (IL-12, IFN-γ) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine levels, along with IL-1β, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3, were observed in COVID-19 cases. We demonstrated the diagnostic potential of some clinical and immune factors to differentiate COVID-19 from pandemic influenza A(H1N1). Our data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory response that is different from the immune response against influenza. These findings might be relevant for the upcoming 2020-2021 influenza season, which is projected to be historically unique due to its convergence with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJAPC was supported by the National Council of Science and Technology of Mexico to achieve (CONACyT) his PhD degree (CONACyT-CVU 737347). The current study was supported by institutional research funds of INER and by research contracts: SECTEI/050/2020, Secretaria de Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico (SECTEI CDMX); FORDECyT/10SE/2020/05/14-06 and FORDECyT/10SE/2020/05/14-07 from the Fondo Institucional de Fomento Regional para el Desarrollo Cientifico y Tecnologico y de Innovacion (FORDECyT) of the CONACyT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ, approval number: 3349) and the Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER, approval number: B28-16 and B09-20) in Mexico City approved the study. All participants or their legal guardians provided written informed consent in accordance with the Declaration of Helsinki for Human Research. Clinical samples were managed according to the Mexican Constitution law NOM-012-SSA3-2012, which establishes the criteria for the execution of clinical investigations in humans.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe databases used in the current study are available from the corresponding author on reasonable request